Sorafenib (tosylate)

Sorafenib (tosylate)
Artikelnummer Größe Datenblatt Manual SDB Lieferzeit Menge Preis
Cay35612-5 5 g -

6 - 10 Werktage*

87,00 €
Cay35612-10 10 g -

6 - 10 Werktage*

153,00 €
Cay35612-25 25 g -

6 - 10 Werktage*

317,00 €
Cay35612-50 50 g -

6 - 10 Werktage*

467,00 €
 
Sorafenib is a multi-kinase inhibitor that inhibits Raf-1 and B-RAF (IC50s = 6 and 22 µM,... mehr
Produktinformationen "Sorafenib (tosylate)"
Sorafenib is a multi-kinase inhibitor that inhibits Raf-1 and B-RAF (IC50s = 6 and 22 µM, respectively), as well as the receptor tyrosine kinases VEGFR2, VEGFR3, PDGFRbeta, FLT3, and c-Kit (IC50s = 90, 15, 20, 57, and 58 nM, respectively). It is selective for these kinases over 12 other kinases, including ERK1, MEK1, EGFR, and HER2 (IC50s = >10 µM for all). Sorafenib inhibits proliferation of PLC/PRF/5 and HepG2 cells (IC50s = 6.3 and 4.5 µM, respectively) and induces apoptosis in these cells. It completely inhibits tumor growth in a PLC/PRF/5 mouse xenograft model when administered at a dose of 30 mg/kg and reduces basic FGF-induced angiogenesis in a Matrigel(TM) assay in vivo. Sorafenib (10 µM) induces ferroptotic cell death in HT-1080 fibrosarcoma cells, an effect that can be blocked by the ferroptosis inhibitors ferrostatin-1 (Cay-17729), deferoxamine (Cay-14595), and beta-mercaptoethanol, but does not induce ferroptosis in a variety of other cancer cell lines. It inhibits glutamate release by the system xc- cystine/glutamate transporter in HT-1080 cells when used at concentrations ranging from 2.5 to 10 µM, decreases glutathione levels, and increases lipid peroxidation. Sorafenib also inhibits replication of hepatitis C virus (HCV) in Huh7.5 cells (IC50 = 7.2 µM). Formulations containing sorafenib have been used in the treatment of hepatocellular, renal cell, and thyroid carcinomas.Formal Name: 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide, 4-methylbenzenesulfonate. CAS Number: 475207-59-1. Synonyms: BAY 43-9006 mono-p-tosylate, BAY 54-9085. Molecular Formula: C21H16ClF3N4O3 . C7H8O3S. Formula Weight: 637.0. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMF: 3 mg/ml, DMSO: 5 mg/ml, Ethanol: insol, PBS (pH 7.2): insol. lambdamax: 266 nm. SMILES: O=C(NC1=CC(C(F)(F)F)=C(Cl)C=C1)NC2=CC=C(OC3=CC=NC(C(NC)=O)=C3)C=C2.O=S(O)(C4=CC=C(C)C=C4)=O. InChi Code: InChI=1S/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25,1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31),2-5H,1H3,(H,8,9,10). InChi Key: IVDHYUQIDRJSTI-UHFFFAOYSA-N.
Schlagworte: BAY 43-9006 mono-p-tosylate, BAY 54-9085, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide, 4-methylbenzenesulfonate
Hersteller: Cayman Chemical
Hersteller-Nr: 35612

Eigenschaften

Anwendung: Multi-kinase inhibitor
MW: 637 D
Formel: C21H16ClF3N4O3 . C7H8O3S
Reinheit: >98%
Format: Solid

Datenbank Information

CAS : 475207-59-1| Passende Produkte
KEGG ID : K05089 | Passende Produkte

Handhabung & Sicherheit

Lagerung: -20°C
Versand: +20°C (International: -20°C)
Signalwort: Danger
GHS-Piktogramme:
H-Sätze: H302, H332, H360, H362, H373, H412, H402
P-Sätze: P201, P202, P260, P261, P263, P264, P270, P271, P273, P280, P312, P314, P330, P301+P310, P304+P340, P308+P313, P405, P501
Achtung
Nur für Forschungszwecke und Laboruntersuchungen: Nicht für die Anwendung im oder am Menschen!
Hier kriegen Sie ein Zertifikat
oder , um Analysenzertifikate anzufordern.
Bewertungen lesen, schreiben und diskutieren... mehr
Kundenbewertungen für "Sorafenib (tosylate)"
Bewertung schreiben
oder , um eine Produktbewertung abzugeben.
Zuletzt angesehen